TGFB1 and Marfan syndrome: Data on the use of angiotensin-converting enzyme inhibitor (ACEI)22,23 and angiotensin-receptor blocker (ARB)11,24 to slow progression of aortic root dilation through modulation of the TGF-β1 signaling pathway in Marfan syndrome are encouraging.